ClinicalTrials.gg
WithdrawnNCT01947842Updated Feb 15, 2023

Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females

An interventional study of Smartphone App Dosecast in Adherence to Oral Contraceptive Therapy, sponsored by Belmont University. Withdrawn at 3 sites in United States. Open to female participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Belmont University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Funding unavailable.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 29 Years
Sex
Female
01

Study summary

This research study is to see if smartphone applications help college women remember to take birth control better than pharmacist consultation alone. Patients will participate in this study for 6 (six) months. The study will have two groups. Patients will be randomly assigned to one group or the other. The control group will be counseled by the pharmacist on the importance of taking birth control as prescribed. The study group will get the same counseling, but will also be set up to receive reminders to take medication on a smartphone application called Dosecast.

02

Conditions studied

  • Adherence to Oral Contraceptive Therapy

Keywords

  • Smartphone
  • adherence
  • contraceptives
  • college
  • females
03

In context

Lead sponsor

Belmont University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female gender
  • 18-29 years of age
  • current prescription for an OCP
  • currently enrolled as a student at the institution associated with the pharmacy
  • possession of a compatible smartphone.

Exclusion criteria

Exclusion Criteria:

  • Pregnant patients
  • Patients who become pregnant during the study will discontinue, but their data up until time of discontinuation will be used
  • Patients using other forms of (patch, injection, IUD, intra-vaginal ring, implant).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Smartphone App

    The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.

    Device: Smartphone App Dosecast

  • No intervention
    Counseling Alone

    This arm will receive only counseling from the pharmacist with no other intervention.

Interventions

  • DeviceSmartphone App Dosecast

    The Dosecast app is configured to remind the patient to take their medication.

06

What researchers measure

Primary outcomes

  1. Doses Missed

    Number of doses of oral contraceptive missed over a six-month period.

    Time frame: 6 months

07

Study locations

3 sites
  • Auburn University
    Auburn, Alabama 36849, United States
  • University of Mississippi
    Oxford, Mississippi 38677, United States
  • Belmont University
    Nashville, Tennessee 37212, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2013
First posted
Sep 23, 2013
Start
Jan 2014
Primary completionEst.
Dec 2014
CompletionActual
Dec 2014
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01947842
Lead sponsor
Belmont University
Responsible party
Adam Pace (Assistant Professor of Pharmacy Practice, Belmont University) — Principal investigator
First posted
Sep 23, 2013
Start date
Jan 2014
Primary completion
Dec 2014 (estimated)
Completion
Dec 2014
Last update
Feb 15, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion